Sarepta Therapeutics agreed to pay Regenxbio $39 million to settle gene therapy-related claims, underscoring ongoing legal and financial friction in the gene therapy space even after clinical programs progress. The settlement comes as companies continue to manage platform risk, manufacturing scale-up, and post-trial obligations. The item also notes continued fundraising activity tied to emerging gene therapy and rare-disease companies, reflecting that investors still fund the modality despite headline legal disputes. For operators in gene therapy, these settlements influence litigation cost modeling, deal diligence, and partner confidence—especially where ownership, rights, and trial conduct disputes can spill into future licensing and commercialization negotiations.